Outcomes of pregnancy and childbirth in women with hidradenitis suppurativa - 16/07/21

Doi : 10.1016/j.jaad.2021.05.059

Surav Man Sakya, BS ^a, David R. Hallan, MD ^b, Steven A. Maczuga, MS ^c, Joslyn S. Kirby, MD, MS, MEd ^c,^⁎
^a School of Medicine, Penn State College of Medicine, Hershey, Pennsylvania
^b Department of Neurosurgery, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania
^c Department of Dermatology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania

^∗Correspondence to: Joslyn S. Kirby, MD, MS, MEd, Associate Professor of Dermatology, Department of Dermatology, Penn State Milton S. Hershey Medical Center, 500 University Dr, HU 14, Hershey, PA 17033.Associate Professor of DermatologyDepartment of DermatologyPenn State Milton S. Hershey Medical Center500 University DrHU 14HersheyPA17033

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Friday 16 July 2021
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Abstract

Background

Many women affected by hidradenitis suppurativa (HS) are of childbearing age. To date, the literature is limited on pregnancy-related outcomes for women with HS.

Objective

To investigate maternal and obstetric outcomes and treatment utilization among women with HS.

Methods

This retrospective analysis used the IBM MarketScan Commercial Claims Database. Pregnant women with HS (n = 998) and 5:1 age-matched pregnant women without HS (n = 5065) were identified and information on claims related to diagnoses, procedures, and medications were analyzed.

Results

Compared to women without HS, pregnant women with HS had significantly lower odds of having a live birth (odds ratio [OR], 0.45; 95% confidence interval [CI], 0.39-0.51) and significantly higher odds of having elective terminations (OR, 2.51; 95% CI, 2.13-2.96), gestational hypertension (OR, 1.44; 95% CI, 1.12-1.84), and cesarean deliveries (OR, 1.28; 95% CI, 1.06-1.55), and of receiving HS designated treatment during pregnancy (OR, 4.41; 95% CI, 3.56-5.46).

Limitations

Retrospective and convenience sampling and absence of clinical information to correlate HS severity and outcomes.

Conclusion

Pregnant women with HS have an increased probability of select complicated maternal and obstetric outcomes. Women planning for pregnancy or who are currently pregnant may benefit from coordinated care by dermatologists and obstetric providers.

Le texte complet de cet article est disponible en PDF.

Key words : acne inversa, biologics, health services research, hidradenitis suppurativa, outcomes, pregnancy, surgery

Abbreviations used : CI, HS, OR, RA, SLE

Plan

Pregnancy complications and delivery

Common HS medication and procedure use

Discussion

Conclusion

	Funding sources: None.
	Portions of this study have been presented virtually at the Symposium on Hidradenitis Suppurativa Advances (SHSA), October 9-11, 2020.
	IRB approval status: Exempted from review.
	Reprints not available from the authors.